CLOs on the Move

Terumo Blood and Cell Technologies

www.terumobct.com

 
Headquartered in Lakewood, Colorado, Terumo Blood and Cell Technologies is a global leader in blood component, therapeutic apheresis and cellular technologies serving customers in more than 130 countries. As the only company with the unique combination of apheresis collections, manual and automated whole blood processing and pathogen reduction, we believe in the potential of blood to do even more for patients than it does today. This belief unites our organization, inspires our innovation and strengthens our collaboration with customers. Originally established in 1964 as COBE Laboratories, today, nearly 7,000 associates around the world are deeply committed to our vision of ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.terumobct.com
  • 10811 W Collins Avenue
    Lakewood, CO USA 80215
  • Phone: 303.232.6800

Executives

Name Title Contact Details
Elizabeth Reagan
Assistant General Counsel, Director of Intellectual Property Profile
Janet Johnson
Vice President, Global Regulatory Affairs Profile

Similar Companies

Alternatives Technologies Pharma

Alternatives Technologies Pharma Inc. is a Chicoutimi, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Concerro

Concerro is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bellerophon Therapeutics

Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases.

Kosan Biosciences

Kosan Biosciences Incorporated is a Hayward, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Scipher Medicine

Most patients who are prescribed blockbuster therapies today don`t respond to the treatment, costing the health care industry billions in wasted drugs while patients continue to suffer. Scipher`s platform identifies which drug will work based on the patient`s fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A simple test predicts which drug he/she will respond to, ensuring that most optimal treatment is prescribed from day one. The molecular data generated by our tests is then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy.